Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02905669
Other study ID # 69HCL16_0457
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 13, 2017
Est. completion date May 25, 2024

Study information

Verified date March 2022
Source Hospices Civils de Lyon
Contact Sabine ROMAN, MD, PhD
Phone +33472110146
Email sabine.roman@chu-lyon.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Impedance planimetry using Endoscopic Functional Lumen Imaging Probe (EndoFLIP) device is a promising diagnostic tool to assess esophageal, esophago-gastric junction and pylorus function. It allows the measurement of esophageal and pylorus distensibility as well as contractile activity in response to distension. Examination is useful performed under sedation. General anesthesia might affect distensibility values. The aim of this study is to normal values for esophageal, esophago-gastric junction and pylorus distensibility in controls during an upper gastro-intestinal endoscopy performed under general anesthesia.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date May 25, 2024
Est. primary completion date May 25, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Subject older than 18 years and younger than 80 years - Subject referred for upper gastro-intestinal endoscopy under general anesthesia for anemia, intestinal metaplasia in the stomach, Helicobacter pylori screening, or submucosal dissection - Subject with health insurance - Written informed consent Exclusion Criteria: - Patient younger than 18 years or older than 80 years - Pregnancy or breast feeding - Previous history of esophago-gastric surgery or vagotomy - Previous history of Parkinson disease or diabetes mellitus - Contra-indication to upper gastro-intestinal endoscopy - Esophageal varices - Esophageal diameter smaller than 5 mm - Contra-indication to general anesthesia - Hiatal hernia greater than 3 cm on endoscopy - Esophageal or gastric cancer otherwise than superficial lesion with indication of submucosal dissection - Typical symptoms (heartburn, regurgitation) of gastro-esophageal reflux disease and/or gastroesophageal reflux disease (GERD)-Q score greater or equal to 8 - Nausea, vomiting or epigastric pain - Dysphagia with Sydney score greater ou equal to 50 - Incapability to give consent - No written informed consent - Participation to another study at the same time

Study Design


Intervention

Device:
EndoFLIP
Esophago-gastric junction distensibility will be assessed in patients thanks to impedance planimetry using EndoFLIP device

Locations

Country Name City State
France Exploration Fonctionnelle Digestive, Hôpital Edouard Herriot LYON cedex 03

Sponsors (1)

Lead Sponsor Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Esophago-gastric junction distensibility The day of gastro-intestinal endoscopy
Secondary Esophageal distensibility The day of gastro-intestinal endoscopy
Secondary Pylorus distensibility The day of gastro-intestinal endoscopy
Secondary Esophageal contractile activity in response to distension distension volume for presence of esophageal repetitive contraction The day of gastro-intestinal endoscopy
Secondary Side effects occurence Occurrence of pain, aspiration and vomiting The day of gastro-intestinal endoscopy
Secondary Side effects occurence Occurrence of pain, aspiration and vomiting The day after gastro-intestinal endoscopy
See also
  Status Clinical Trial Phase
Completed NCT01012960 - Opioids and Esophageal Function Phase 4